ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Circulating Exosomes with Cardiac Self-Antigens, Myosin and Vimentin, Induced Immune Responses Leading to Rejection Following Heterotopic Cardiac Transplantation Immunosuppressed with mTOR Inhibitor and Low Dose of IL-2 Therapy

Y. Itabashi, R. Ravichandran, S. Bansal, T. Fleming, T. Mohanakumar

Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ

Meeting: 2020 American Transplant Congress

Abstract number: B-380

Keywords: Autoimmunity, Heart/lung transplantation, Immune deviation, Tolerance

Session Information

Session Name: Poster Session B: Tolerance / Immune Deviation

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: The aim of the study is to determine the role for circulating exosomes with cardiac self-antigens (SAgs) (Myosin, Vimentin) in the development of immune responses leading to rejection following heterotopic cardiac transplantation (HTx) immunosuppressed with mTOR inhibitor and low dose of IL-2. It has been proposed that IL-2 may selectively induce proliferation of T regulatory cells leading to graft acceptance.

*Methods: Allogenic (BALB/c to C57BL/6) HTx was performed heterotopically in the abdominal cavity. Immunosuppression was given with mTOR inhibitor, Rapamycin (RAPA) 1mg/kg/day (d), i.p. days 0 – +8 or small dose of IL-2 (30000 IU) i.p., or Rapamycin 1mg/kg i.p days 0 – +8 and IL2 (30,000IU). Sera were analyzed for antibody (Ab) development and characterization of exosomes by western blot was done using specific Abs.

*Results: HTx without any immunosuppression rejected on days 6-8 mean survival time. IL-2 (30000 IU) alone did not significantly prolong graft survival as compared to no treatment (mean survival time) (9.5 vs 6 days (d)). IL2 demonstrated induction of circulating exosomes containing SAgs; Myosin (>3.2fold (f)) and Vimentin (>3.5f) at the time of rejection and interestingly had higher levels PDL1 (>1.8 f), CD73 (>2.2 f), markers associated with allograft tolerance. RAPA treatment significantly prolonged allograft survival (16d p=0.0177) and RAPA +IL2 further prolonged cardiac allograft survival significantly (28d p=0.002). Increased levels of Abs to Vimentin occurred on day 28 when rejection was observed in the RAPA+IL-2 group (124.5±12.6 ng/ml vs 49.2±23.7 ng/ml control; p<0.05). IL2+RAPA group also demonstrated induction of circulating exosomes containing SAgs; Myosin (>3f) and Vimentin (>2.5f), respectively on day 28. Masson staining revealed myocyte damage and fibrosis in RAPA+IL-2 group suggesting antibody mediated damage.

*Conclusions: RAPA and IL2 therapy significantly promoted graft survival following HTx. Low dose IL-2 therapy led to circulating exosomes containing not only cardiac SAgs but also markers associated with tolerance (PDL1 and CD73). However, exosomes with cardiac SAgs could override the influence of PDL1 and CD73 resulting in Ab development to cardiac SAgs leading to rejection of allografts.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Itabashi Y, Ravichandran R, Bansal S, Fleming T, Mohanakumar T. Circulating Exosomes with Cardiac Self-Antigens, Myosin and Vimentin, Induced Immune Responses Leading to Rejection Following Heterotopic Cardiac Transplantation Immunosuppressed with mTOR Inhibitor and Low Dose of IL-2 Therapy [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/circulating-exosomes-with-cardiac-self-antigens-myosin-and-vimentin-induced-immune-responses-leading-to-rejection-following-heterotopic-cardiac-transplantation-immunosuppressed-with-mtor-inhibitor-a/. Accessed May 15, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences